- Lucid Diagnostics (LUCD, Financial) to be included in the Russell 2000® and Russell 3000® indexes effective June 27, 2025.
- Inclusion increases visibility to institutional investors and potential for enhanced trading volume.
- Approximately $10.6 trillion in assets are benchmarked against Russell U.S. Indexes.
Lucid Diagnostics Inc. (NASDAQ: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), will join the Russell 2000® Index and the Russell 3000® Index. This inclusion will take effect after the close of U.S. equity markets on June 27, 2025, as part of the annual reconstitution spearheaded by FTSE Russell.
The Russell 3000 Index comprises the largest 3,000 U.S. public companies by market capitalization, while the Russell 2000 Index is a subset focused on small-cap companies. Membership in these indexes is anticipated to provide Lucid Diagnostics with increased visibility among institutional investors, as well as a potential boost in trading volume and liquidity due to index-linked financial products.
According to FTSE Russell, an impressive $10.6 trillion in assets are benchmarked against the Russell U.S. Indexes, which are extensively utilized by investment managers and institutional investors for index funds and to guide active investment strategies.
Lucid Diagnostics is recognized for its focus on patients with gastroesophageal reflux disease (GERD) at risk of developing esophageal precancer and cancer. Their pioneering EsoGuard® Esophageal DNA Test is performed using the EsoCheck® Esophageal Cell Collection Device, marking a leap in early detection of esophageal precancer in at-risk patients.
